Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705607 | 1.00 | KDM5A (0.32) | KDM5AKDM7AKDM4CPHF8KDM2A | |
| SCHEMBL482044 | 0.87 | NR1H2 (0.33) | — | |
| SCHEMBL343055 | 0.87 | NR1H2 (0.33) | — | |
| SCHEMBL482043 | 0.87 | NR1H2 (0.33) | — | |
| SCHEMBL527479 | 0.84 | DPP4 (0.30) | — | |
| SCHEMBL4877014 | 0.84 | HSD11B1 (0.33) | KDM5AKDM7AKDM4CPHF8KDM2A | |
| SCHEMBL2167298 | 0.84 | KDM5A (0.31) | KDM5AKDM7AKDM4CPHF8KDM2A | |
| SCHEMBL16337286 | 0.84 | HSD11B1 (0.33) | KDM5AKDM7AKDM4CPHF8KDM2A | |
| SCHEMBL2167294 | 0.84 | KDM5A (0.31) | KDM5AKDM7AKDM4CPHF8KDM2A | |
| SCHEMBL16338311 | 0.83 | KDM5A (0.36) | KDM5AKDM7AKDM4CPHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682993-B2 | Anticancer compounds | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160009728-A1 | ANTICANCER COMPOUNDS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2016-01-14 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KDM5A 1548/4885KDM7A 2992/4885KDM4C 3794/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | KDM5A 4161/4885KDM7A 3102/4885KDM4C 3290/4885 |
| US-20160009728-A1 | ANTICANCER COMPOUNDS | MKI67, TP53, BAX | KDM5A 3115/4885KDM7A 3538/4885KDM4C 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.